文献速递胸部肿瘤放疗放疗物理与技术姑息放疗与转移瘤

针对非小细胞肺癌(含寡转移)的立体定向体部放疗转化研究:考虑癌症干样细胞使体外数据可预测临床结局

Translational study for stereotactic body radiotherapy against non-small cell lung cancer, including oligometastases, considering cancer stem-like cells enable predicting clinical outcome from in vitro data.
PubMed 文献 · Radiother Oncol · 2023-02-14

本研究建立考虑子代细胞与癌症干样细胞两群体的细胞杀伤与肿瘤控制概率(TCP)模型,参数取自A549与EBC-1细胞体外存活数据,并用弘前大学医院553例患者临床数据验证。整合微剂量动力学(IMK)模型成功再现急性照射后体外存活及6–10 Gy/次不同分割方案的3年TCP,表明放射抵抗的癌症干样细胞是连接体外与临床结局的关键。

要点

  • 考虑癌症干样细胞的IMK模型可再现A549与EBC-1细胞急性照射后体外存活。
  • 该模型成功再现553例患者6–10 Gy/次分割方案的3年TCP。
  • 不考虑癌症干样细胞的传统预测无法实现体外与临床结局的链接。

核心结论

  • 考虑癌症干样细胞的建模方法提供了可能通用的生物物理模型,使立体定向体部放疗的精确估计可在世界范围内实现。

研究设计与样本

  • 转化研究,建立考虑子代细胞与癌症干样细胞两群体的细胞杀伤与肿瘤控制概率模型。
  • 模型参数取自A549与EBC-1细胞的体外存活数据。
  • 基于细胞参数预测TCP,并与弘前大学医院收集的553例患者临床数据比较。

主要发现

  • 整合微剂量动力学(IMK)模型成功再现急性照射后体外存活及6–10 Gy/次不同分割方案的3年TCP。
  • 不考虑癌症干样细胞的传统预测未能实现体外与临床结局的链接。
  • 放射抵抗的癌症干样细胞在体外与临床结局的链接中起关键作用。

关键数值与推荐

  • 模型参数由A549与EBC-1细胞体外存活数据确定。
  • 临床验证数据来自553例患者,分割方案为6–10 Gy/次。
  • 预测指标为3年TCP。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Curative effects of stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) have been evaluated using various biophysical models. Because such model parameters are empirically determined based on clinical experience, there is a large gap between in vitro and clinical studies. In this study, considering the heterogeneous cell population, we performed a translational study to realize the possible linkage based on a modeling approach. METHODS: We modeled cell-killing and tumor control probability (TCP) considering two populations: progeny and cancer stem-like cells. The model parameters were determined from in vitro survival data of A549 and EBC-1 cells. Based on the cellular parameters, we predicted TCP and compared it with the corresponding clinical data from 553 patients collected at Hirosaki University Hospital. RESULTS: Using an all-in-one developed model, the so-called integrated microdosimetric-kinetic (IMK) model, we successfully reproduced both in vitro survival after acute irradiation and the 3-year TCP with various fractionation schemes (6-10 Gy per fraction). From the conventional prediction without considering cancer stem cells (CSCs), this study revealed that radioresistant CSCs play a key role in the linkage between in vitro and clinical outcomes. CONCLUSIONS: This modeling study provides a possible generalized biophysical model that enables precise estimation of SBRT worldwide.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Saga R, Matsuya Y, Sato H, et al. Translational study for stereotactic body radiotherapy against non-small cell lung cancer, including oligometastases, considering cancer stem-like cells enable predicting clinical outcome from in vitro data. Radiother Oncol. 2023. PMID: 37011969. doi:10.1016/j.radonc.2022.109444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。